Patent revocations in India may spread to other regions (or not) say legal experts
This article was originally published in Scrip
Executive Summary
Patent revocations in a string of high-profile cases in India in 2012, including those concerning Pfizer’s Sutent (sunitinib malate) and Roche’s Pegasys (pegylated interferon alfa-2a) may be factored in as important reference points by other developing nations in future, some legal experts warn.